Skip to main content

From the Helm: CSL’s David Lamont on the biotech giant’s bright future

Jessica Amir
February 20, 2020

In the latest instalment of Bell Direct’s From the Helm series, Jess has a chat with CSL’s CFO David Lamont.

David gives the inside scoop on CSL, the market leader in the blood plasma and vaccine market. Additionally, he explains CSL’s own products, programmes and partnerships, and the steps taken by the medical giant to tackle coronavirus.

Plus, he sheds some light on the unique situation the broader pharmaceuticals industry finds itself in when it comes to new competition, as well as CSL’s future proofing strategy.

Morning Bell 17 March

Jessica Amir
March 17, 2020

Market Update 16 March

Bell Direct
March 16, 2020

Weekly Wrap 13 March

Jessica Amir
March 13, 2020

Market Update 12 March

Paulina Peters
March 12, 2020

Morning Bell 11 March

Jessica Amir
March 11, 2020

ETF mini-series 3/3: Top ETF picks

Jessica Amir
March 10, 2020

Morning Bell 10 March

Jessica Amir
March 10, 2020

Market Update 9 March

Jessica Amir
March 9, 2020

Weekly Wrap 6 March

Jessica Amir
March 6, 2020